CCCCC4 Therapeutics, Inc.
$2.85+26% 1Y
$2.85
$1.7152 weeks$4.67
Is the price fair?
What CCCC's price assumes
C4 Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 8.34× revenue.
8.34
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.24
Price / book · as of 2026-Q1
- EV / sales
- 8.26
EV / sales
Details›
- Price / bookas of 2026-Q1
- 1.24
- EV / EBIToperating margin −319%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 8.26
- Market capitalisation
- $315M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.